There are a number of medications approved by the FDA for the treatment of overweight or obesity. The decision to initiate drug therapy in people considered overweight is made after the consideration of risks and benefits. The goal of any treatment (including drug therapy) for people considered overweight is long term reduction and improvement of overall health.

request an appointment
Phentermine-used for short term use for weight loss, decreases appetite and stimulates metabolism.

Phentermine-toprimate extended release is an option for males and post-menopausal females with obesity who cannot tolerate GLP-1 receptor agonist therapy.

Bupropion-naltrexone-sustained release can be a option for individuals that also desire smoking cessation and has obesity.

Semaglutide is a GLP-1 agonist approved for the treatment of obesity and is administered as a once weekly subcutaneous injection. It has demonstrated efficacy in weight reduction, as well as improvement in glycemia and lipids.

Mounjaro-dual acting GLP-1 and glucose dependent insulin tropic polypeptide may be more effective in achieving weight loss.

AOD 9604-a peptide that regulates fat metabolism without the adverse effects on blood sugar. Stimulates lipogenesis which reduces body fat, regulates fat metabolism and stimulates lipolysis.

Mots-C is a peptide that improves glucose utilization and insulin sensitivity resulting in reducing fat accumulation and increases metabolism.